Zions Bancorporation National Association UT Has $4.46 Million Holdings in Gilead Sciences, Inc. $GILD

Zions Bancorporation National Association UT decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 32.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,172 shares of the biopharmaceutical company’s stock after selling 18,883 shares during the quarter. Zions Bancorporation National Association UT’s holdings in Gilead Sciences were worth $4,459,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GILD. Rothschild Investment LLC increased its position in shares of Gilead Sciences by 1.9% during the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after purchasing an additional 84 shares in the last quarter. Hemington Wealth Management boosted its position in Gilead Sciences by 9.3% in the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 85 shares in the last quarter. Ignite Planners LLC grew its stake in Gilead Sciences by 1.1% during the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after buying an additional 86 shares during the last quarter. Archer Investment Corp increased its holdings in shares of Gilead Sciences by 1.2% during the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock worth $807,000 after buying an additional 87 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. boosted its holdings in shares of Gilead Sciences by 0.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 34,711 shares of the biopharmaceutical company’s stock worth $3,912,000 after acquiring an additional 87 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at $1,115,713.60. This represents a 35.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at $76,504,230. The trade was a 16.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 288,891 shares of company stock worth $40,303,946 in the last ninety days. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Up 2.1%

GILD opened at $154.98 on Monday. The firm has a 50 day simple moving average of $130.27 and a 200 day simple moving average of $122.38. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The company has a market cap of $192.28 billion, a price-to-earnings ratio of 22.89, a price-to-earnings-growth ratio of 2.06 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.1%. Gilead Sciences’s payout ratio is currently 46.68%.

Analysts Set New Price Targets

A number of research firms recently weighed in on GILD. Needham & Company LLC raised their price target on Gilead Sciences from $140.00 to $170.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Morgan Stanley lifted their price target on Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Wolfe Research raised their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday. Wall Street Zen lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Finally, Mizuho raised their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Twenty-three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $152.50.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported better-than-expected Q4 results and raised FY26 guidance, driving optimism about near-term revenue and EPS trends. Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets
• Positive Sentiment: Major analysts lifted price targets and/or maintained Buy/Outperform ratings after the results — Wolfe Research to $170 (outperform), Oppenheimer to $165 (outperform), TD Cowen to $160 (buy), Deutsche Bank to $155 (buy) — signaling analyst conviction and providing upward pressure on the stock. Wolfe Research price target raise
• Positive Sentiment: BofA raised its price target to $162 and reiterated a Buy, reflecting post‑earnings confidence in Gilead’s franchises. BofA raises PT
• Positive Sentiment: Additional buy ratings from large banks — J.P. Morgan and Scotiabank reiterated/issued Buy calls — adding to institutional endorsement after results. J.P. Morgan buy Scotiabank buy
• Positive Sentiment: Pipeline & product catalysts: Yescarta label expansion and continued HIV franchise momentum (Biktarvy, Descovy, Yeztugo) are being highlighted as durable growth drivers and part of the investment case. Yescarta label expansion & dividend growth
• Neutral Sentiment: Analyst commentary and research pieces (Zacks articles) are flagging Gilead as a momentum/value candidate and discussing whether the HIV portfolio can sustain growth — useful context but not immediate catalysts. Zacks momentum Zacks on HIV portfolio
• Neutral Sentiment: Short‑interest reports in the feed show zero shares / NaN changes and a 0.0 days-to-cover — likely a reporting/data artifact rather than a meaningful market signal. (No external link available in the entry.)

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.